PTHS — Pelthos Therapeutics Inc.

Pelthos Therapeutics Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Net Product Revenue: $7.1 million for Q3 2025, driven by the launch of ZELSUVMI.
• Operating Loss: $15.4 million for the quarter; GAAP net loss of $16.2 million ($5.30 per share).
• As-Converted Loss: $1.83 per share when factoring in convertible preferred stock.
• Cash Position: $14.2 million in cash and $8 million in accounts receivable as of September 30, 2025.
• Gross-to-Net (GTN): 25.3% for Q3; expected to rise to mid- to high 30% range by Q1 2026.
• Sales Force: Currently 50 representatives, with plans to expand by 14 to cover more metropolitan areas.

2. Strategic Updates and Business Highlights:

• Product Launch: ZELSUVMI, a topical treatment for molluscum contagiosum, launched in mid-July 2025, is the first FDA-approved at-home therapy for the condition.
• Acquisition of Xepi: Recently acquired Xepi, a treatment for impetigo, to complement ZELSUVMI. The acquisition cost was $4.2 million upfront, with additional milestone payments.
• Sales Performance: Strong initial demand for ZELSUVMI, with over 4,900 units shipped to wholesalers and nearly 3,000 to pharmacies in Q3.
• Market Position: ZELSUVMI is positioned as a first-line treatment, with a focus on pediatric patients and their caregivers.

3. Forward Guidance and Outlook:

• Cash Flow Breakeven: Expected by the end of 2026, driven by ZELSUVMI's growth and responsible spending.
• Revenue Projections: Anticipating significant revenue growth in Q4 2025, with a current annual gross revenue run rate of approximately $52 million.
• Expansion Plans: Additional sales representatives to be hired and trained by mid-January 2026 to enhance market penetration.

4. Bad News, Challenges, or Points of Concern:

• Operating Losses: Continued operating losses with a significant net loss reported, raising concerns about sustainability in the near term.
• Seasonality Impact: Potential softening of prescription growth during the holiday season due to reduced patient visits to healthcare providers.
• Market Competition: The need to establish strong market presence against existing treatments and ensure favorable payer contracts.

5. Notable Q&A Insights:

• Prescriber Engagement: Approximately 60% of unique prescribers have written one prescription, with some writing multiple. Coverage currently targets about 8,000 accounts, with plans to expand to 10,000.
• Refill Rates: Initial prescriptions are for 30 days, with expectations of 1.2 units per patient on average for those requiring extended treatment.
• Pricing Strategy: Management indicated a cautious approach to pricing, with potential for responsible increases in the future, particularly as they do not currently have commercial contracts affecting rebates.
• Future Acquisitions: While Xepi is the current focus, Pelthos is open to exploring additional complementary products in the dermatology space.

Overall, Pelthos Therapeutics has made a strong start with the launch of ZELSUVMI, but faces challenges related to ongoing losses, potential seasonal impacts on sales, and the competitive landscape. The company is optimistic about its growth trajectory and strategic initiatives moving forward.